Anthony Rhodes

List of Publications by Year
in descending order

48 papers	10,711 citations	257101 24 h-index	253896 43 g-index
48 all docs	48 docs citations	48 times ranked	10396 citing authors

#	Article	IF	Citations
1	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology, 2007, 26, 118-145.	0.8	3,139
2	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	0.8	2,667
3	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2007, 131, 18-43.	1.2	1,359
4	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	1.2	855
5	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	1.2	697
6	Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. Journal of Clinical Pathology, 2000, 53, 125-130.	1.0	290
7	Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. Journal of Clinical Pathology, 2000, 53, 634-635.	1.0	170
8	Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-Fixed and Paraffin-Processed Cell Lines and Breast Tumors. American Journal of Clinical Pathology, 2002, 118, 408-417.	0.4	164
9	Best Practice No 176: Updated recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 2004, 57, 233-237.	1.0	156
10	Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. Journal of Clinical Pathology, 2000, 53, 688-696.	1.0	150
11	Study of Interlaboratory Reliability and Reproducibility of Estrogen and Progesterone Receptor Assays in Europe. American Journal of Clinical Pathology, 2001, 115, 44-58.	0.4	148
12	Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. Journal of Clinical Pathology, 2000, 53, 292-301.	1.0	138
13	Estrogen and progesterone receptors in breast cancer. Future Oncology, 2014, 10, 2293-2301.	1.1	127
14	A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast Cancer. American Journal of Clinical Pathology, 2002, 117, 81-89.	0.4	87
15	Antigen Unmasking in Formalin-Fixed Routinely Processed Paraffin Wax-Embedded Sections by Pressure Cooking. Advances in Anatomic Pathology, 1995, 2, 60-64.	2.4	66
16	Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Research, 2012, 14, R142.	2.2	44
17	Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer. American Journal of Clinical Pathology, 2014, 141, 323-333.	0.4	44
18	The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?. Journal of Clinical Pathology, 2009, 62, 95-96.	1.0	43

#	Article	IF	Citations
19	Metabolic role of fatty acid binding protein 7 in mediating triple-negative breast cancer cell death via PPAR-Î± signaling. Journal of Lipid Research, 2019, 60, 1807-1817.	2.0	41
20	The Use of Cell Line Standards to Reduce HER-2/neu Assay Variation in Multiple European Cancer Centers and the Potential of Automated Image Analysis to Provide for More Accurate Cut Points for Predicting Clinical Response to Trastuzumab. American Journal of Clinical Pathology, 2004, 122, 51-60.	0.4	38
21	Quantitative Analysis of ERG Expression and Its Splice Isoforms in Formalin-Fixed, Paraffin-Embedded Prostate Cancer Samples. American Journal of Clinical Pathology, 2014, 142, 533-540.	0.4	33
22	Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. Journal of Clinical Pathology, 2004, 57, 687-690.	1.0	27
23	The Reliability of Rabbit Monoclonal Antibodies in the Immunohistochemical Assessment of Estrogen Receptors, Progesterone Receptors, and HER2 in Human Breast Carcinomas. American Journal of Clinical Pathology, 2010, 134, 621-632.	0.4	26
24	The Estrogen Receptor Negative-Progesterone Receptor Positive Breast Carcinoma is a Biological Entity and not a Technical Artifact. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1111-1113.	0.5	25
25	Quality Assurance in Immunohistochemistry. American Journal of Surgical Pathology, 2003, 27, 1284-1285.	2.1	24
26	Factors affecting estrogen receptor status in a multiracial Asian country: An analysis of 3557 cases. Breast, 2011, 20, S60-S64.	0.9	23
27	Do Clinical Features and Survival of Single Hormone Receptor Positive Breast Cancers Differ from Double Hormone Receptor Positive Breast Cancers?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7959-7964.	0.5	14
28	Insulin Receptor Isoform Variations in Prostate Cancer Cells. Frontiers in Endocrinology, 2016, 7, 132.	1.5	13
29	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. British Journal of Biomedical Science, 2020, 77, 168-184.	1.2	12
30	TRPM8 agonists modulate contraction of the pig urinary bladder. Canadian Journal of Physiology and Pharmacology, 2013, 91, 503-509.	0.7	10
31	Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung. British Journal of Biomedical Science, 2017, 74, 176-180.	1.2	10
32	Triple negative breast cancer: the role of metabolic pathways. Malaysian Journal of Pathology, 2014, 36, 155-62.	0.1	10
33	Developing a cell line standard for HER2/neu. Cancer Biomarkers, 2005, 1, 229-232.	0.8	9
34	Fatty acid binding protein 7 mediates linoleic acid-induced cell death in triple negative breast cancer cells by modulating 13-HODE. Biochimie, 2020, 179, 23-31.	1.3	8
35	Variation in rates of oestrogen receptor positivity in breast cancer again. BMJ: British Medical Journal, 2002, 324, 298b-298.	2.4	8
36	Fixation of tissues. , 2013, , 69-93.		7

#	Article	IF	Citations
37	Clinico-pathological features of oropharyngeal squamous cell carcinomas in Malaysia with reference to HPV infection. Infectious Agents and Cancer, 2018, 13, 21.	1.2	6
38	The role of heat shock proteins and glucose regulated proteins in cancer. Malaysian Journal of Pathology, 2016, 38, 75-82.	0.1	6
39	Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer. British Journal of Biomedical Science, 2017, 74, 65-70.	1.2	5
40	Immunoglobulin heavy chain patterns in reactive lymphadenopathy.. Journal of Clinical Pathology, 1991, 44, 753-755.	1.0	3
41	Quantification in histopathologyâ€"Can magnetic particles help?. Journal of Magnetism and Magnetic Materials, 2007, 311, 264-268.	1.0	3
42	A M-MLV reverse transcriptase with reduced RNaseH activity allows greater sensitivity of gene expression detection in formalin fixed and paraffin embedded prostate cancer samples. Experimental and Molecular Pathology, 2013, 95, 98-104.	0.9	3
43	Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate. Malaysian Journal of Pathology, 2018, 40, 103-110.	0.1	2
44	Polymorphisms in the androgen receptor CAG repeat sequence are related to tumour stage but not to ERG or androgen receptor expression in Malaysian men with prostate cancer. Malaysian Journal of Pathology, 2019, 41, 243-251.	0.1	1
45	Quality Assurance of Predictive Markers in Breast Cancer. , 2004, 97, 029-058.		0
46	British Journal of Biomedical Science in 2020. What have we learned?. British Journal of Biomedical Science, 2020, 77, 159-167.	1.2	0
47	Breast cancer hormone receptor testing in Asia: is it time to think again on expected positivity rates and methods of scoring?. Pathology, 2020, 52, 385-387.	0.3	0
48	British Journal of Biomedical Science in 2021. What have we learned?. British Journal of Biomedical Science, 2021, 78, 159-166.	1.2	0